CD18 Monoclonal Antibody (MEM-148), Invitrogen™

Description

• This antibody will not cross-react with porcine
• Endotoxin level is less than 0.01 EU/ug of the protein, as determined by the LAL test
• Purity is >95% by SDS-PAGE
• Western blot should be performed under non-reducing conditions
• Functional Application: The antibody MEM-148 induces homotypic cell aggregation and high-affinity LFA-1 conformation in resting leukocytes
• CD18 integrin beta 2 subunit is a 90 kDa type I transmembrane protein expressed on all leucocytes
• CD18 can combine with integrin molecules CD11a-c to form heterodimers at the cell surface, and these heterodimers are known to participate in the process of cell adhesion as well as cell-surface mediated signaling
• CD18 forms heterodimers with four types of CD11 molecule to constitute leukocyte (beta2) integrins: alphaLbeta2 (CD11a/CD18, LFA-1), alphaMbeta2 (CD11b/CD18, Mac-1, CR3), alphaXbeta2 (CD11c/CD18) and alphaDbeta2 (CD11d/CD18)
• In most cases, the response mediated by the integrin is a composite of the functions of its individual subunits, and these integrins are essential for proper leukocyte migration, mediating intercellular contacts
• Absence of CD18 leads to leukocyte adhesion deficiency-1, severe reduction of CD18 expression leads to the development of a psoriasiform skin disease
• CD18 is also a target of Mannheimia (Pasteurella) haemolytica leukotoxin and is sufficient to mediate leukotoxin-mediated cytolysis
• Defects in the CD18 gene are the cause of leukocyte adhesion deficiency type I (LAD1)
• Two transcript variants encoding the CD18 protein have been identified.